{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:07Z","timestamp":1747181107654,"version":"3.40.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The global prevalence of leprosy has decreased substantially, and cases of leprosy infection are extremely rare in China. In this report, we present a case of recurrent choriocarcinoma complicated by leprosy infection during chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 24-year-old Chinese woman (gravida 3, para 2) presented to a local hospital with vaginal bleeding. Her medical history included a previous diagnosis of hydatidiform mole.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses, Interventions and Outcomes:<\/jats:title>\n            <jats:p>The patient was diagnosed with choriocarcinoma and received chemotherapy in 6 cycles. Shortly after the initial treatment was completed, the disease recurred twice with resistance to multiple chemotherapeutic agents. In her second recurrence of choriocarcinoma, she was diagnosed with leprosy with many cutaneous nodules throughout her entire body. The patient was administered chemical treatment for leprosy with the multidrug therapy regimen after being diagnosed. To prevent exacerbating the infection, no immunotherapy was utilized to treat cancer, and the infection was well-controlled at the conclusion of anticancer therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Because of immunological reduction, cancer patients are susceptible to a variety of infections. For patients with cancer, prevention and early detection of rare infectious diseases should receive special attention. Immunotherapy must be used with caution when treating patients with cancer and infections.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034548","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T14:03:29Z","timestamp":1691762609000},"page":"e34548","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent choriocarcinoma complicated with leprosy during chemotherapy: A case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-0931","authenticated-orcid":false,"given":"Shiqi","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, P. R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2290-4532","authenticated-orcid":false,"given":"Qingli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clindermatol.2006.05.012","article-title":"Leprosy.","volume":"25","author":"Walker","year":"2007","journal-title":"Clin Dermatol"},{"key":"R2-20250504","first-page":"1","article-title":"Chemotherapy of leprosy for control programmes.","volume":"675","year":"1982","journal-title":"World Health Organ Tech Rep Ser"},{"key":"R3-20250504","first-page":"501","article-title":"Global leprosy update, 2016: accelerating reduction of disease burden.","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1440-1843.2008.01282.x","article-title":"Solid-organ malignancy as a risk factor for tuberculosis.","volume":"13","author":"Kim","year":"2008","journal-title":"Respirology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00784-019-02864-6","article-title":"Increased risk of tuberculosis in oral cancer patients in an endemic area: a nationwide population-based study.","volume":"23","author":"Teng","year":"2019","journal-title":"Clin Oral Investig"},{"key":"R6-20250504","first-page":"125","article-title":"Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study.","volume":"15","author":"Wu","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/10428194.2018.1499904","article-title":"The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome\/myeloproliferative neoplasm: a large population-based cohort study.","volume":"60","author":"Ganzel","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1086\/503917","article-title":"The risk of tuberculosis in patients with cancer.","volume":"42","author":"Kamboj","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.31557\/APJCP.2020.21.9.2715","article-title":"Incidence of and risk factors for tuberculosis among cancer patients in endemic area: a regional cohort study.","volume":"21","author":"Nanthanangkul","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1186\/s12885-021-08391-6","article-title":"Cancer risk in tuberculosis patients in a high endemic area.","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e2021053","DOI":"10.4084\/MJHID.2021.053","article-title":"Increased risk of lymphoma in men or the elderly infected with tuberculosis.","volume":"13","author":"Li","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.5588\/ijtld.14.0161","article-title":"Tuberculosis and risk of cancer: a Danish nationwide cohort study.","volume":"18","author":"Simonsen","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.","volume":"390","author":"Ghorani","year":"2017","journal-title":"Lancet"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.6004\/jnccn.2019.0053","article-title":"Gestational trophoblastic neoplasia, version 2.2019, NCCN clinical practice guidelines in oncology.","volume":"17","author":"Abu-Rustum","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"R15-20250504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijgo.13877","article-title":"Diagnosis and management of gestational trophoblastic disease: 2021 update.","volume":"155","author":"Ngan","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/IGC.0000000000000892","article-title":"PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes.","volume":"27","author":"Bolze","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases.","volume":"36","author":"Veras","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.humpath.2018.10.001","article-title":"Analysis of PD-L1 expression in trophoblastic tissues and tumors.","volume":"84","author":"Lu","year":"2019","journal-title":"Hum Pathol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jcph.2170","article-title":"Immune checkpoint inhibitors and tuberculosis infection in lung cancer: a case series and systematic review with pooled analysis.","volume":"63","author":"He","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context.","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review.","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2020.03.015","article-title":"Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature.","volume":"132","author":"Zaemes","year":"2020","journal-title":"Eur J Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"727220","DOI":"10.3389\/fimmu.2022.727220","article-title":"Increased tuberculosis incidence due to immunotherapy based on PD-1 and PD-L1 blockade: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R25-20250504","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002960","article-title":"Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.","volume":"9","author":"Bae","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis.","volume":"107","author":"Lazar-Molnar","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition.","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e19864","DOI":"10.1371\/journal.pone.0019864","article-title":"T cells from programmed death-1 deficient mice respond poorly to mycobacterium tuberculosis infection.","volume":"6","author":"Tousif","year":"2011","journal-title":"PLoS One"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"e001664","DOI":"10.1136\/jitc-2020-001664","article-title":"Cancer immunotherapy in special challenging populations: recommendations of the advisory committee of Spanish melanoma group (GEM).","volume":"9","author":"Gonzalez-Cao","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.12968\/jowc.2016.25.5.250","article-title":"Nodular melanoma in trophic ulceration of a leprosy patient: a case study.","volume":"25","author":"Zhu","year":"2016","journal-title":"J Wound Care"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:21:36Z","timestamp":1746325296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":30,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034548","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}